CBDHIGHBIO
Financiado
Strategies to modulate the bioavailability of cannabinoids in edible products: i...
Strategies to modulate the bioavailability of cannabinoids in edible products: in vitro tests, cytotoxicity, and pre-clinical assessment to generate reliable data for regulatory agencies
Cannabis edibles (CE) are considered a big opportunity to take place in the recent and fast-growing cannabis market. However, there are big challenges on the development of these products, such as the lack of understanding of the...
Cannabis edibles (CE) are considered a big opportunity to take place in the recent and fast-growing cannabis market. However, there are big challenges on the development of these products, such as the lack of understanding of the metabolism of cannabinoids after oral ingestion, the low bioavailability of cannabinoids (including cannabidiol, CBD), and high intra- and inter-subjects’ pharmacokinetic variability. Recent approaches to enhance the oral CBD bioavailability include its incorporation into lipid-based delivery systems and the addition of compounds called bioenhancers. Lipids can enhance the oral CBD bioavailability via an increase in the transport to the systemic circulation via intestinal lymph, whereas bioenhancers may inhibit metabolizing enzymes reducing the extent of its liver first-pass effect. Piperine (PIP) is known as a powerful bioenhancer by inhibiting drug-metabolizing enzymes of cytochrome P-450 (CYP450), that are involved in the CBD metabolism. The aims of this study are to provide reliable data about the CBD metabolism after oral ingestion to help regulatory agencies to regulate the market of CE and standardize the consumption indications for these products; to increase the CBD bioavailability by using long-chain fatty acids to promote the enhancement of lymphatic absorption combined with PIP addition to inhibit the hepatic metabolism of CBD; and develop an advanced delivery carrier to enable its vehiculation into aqueous-based CE. We hypothesize that the combination of CBD and PIP can substantially improve the CBD bioavailability, thus decreasing the intra- and inter-subject variability. Systematic in vitro tests will be performed to evaluate the inhibitory effect of PIP on CYP450 activity, to determine the bioaccessibility, stability and bioavailability of CBD and PIP after oral ingestion, and to assess their cytotoxicity. Finally, in vivo studies will be performed to evaluate the CBD pharmacokinetic and bioavailability.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2022-10-17
Fecha Fin: 2024-10-16
Fecha Fin: 2024-10-16
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-16
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01:
MSCA Postdoctoral Fellowships 2021
Cerrada
hace 3 años
Líder del proyecto
UNIVERSIDADE DO MINHO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5